Alvotech is trading at ISK 614.00 (-3.46%), with broad risk-off sentiment the likeliest context. - Reuters reported Nasdaq futures fell nearly 2% as AI-spending concerns and rising oil prices weighed on markets. - October 22 coverage reported a lawsuit challenging AbbVie’s Humira patent defenses, but did not connect it to Alvotech’s share decline. - Alvotech’s latest FDA manufacturing-process announcement was dated October 20, not October 22.